EdgeMarket › What Adar1 Capital Management, Llc reported owning
What Adar1 Capital Management, Llc reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
1.7BPositions
310Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| ABVX Abivax S.A. | 155.2M | 9.1% | 1.4M | 114.95 | +59.9% |
| PTGX Protagonist Therapeutics, Inc | 104.8M | 6.2% | 994.1K | 154.32 | +174.4% |
| ROIV Roivant Sciences Ltd. | 91.0M | 5.4% | 3.3M | 36.30 | +209.7% |
| IMVT Immunovant, Inc. | 66.5M | 3.9% | 2.7M | 44.37 | +199.4% |
| SPY SPDR S&P 500 ETF TRUST | 49.4M | 2.9% | 75.9K | 765.72 | +20.0% |
| unmapped CUSIP 880881107 | 48.2M | 2.8% | 914.7K | — | — |
| CYTK CYTOKINETICS INC | 41.7M | 2.5% | 632.6K | 76.84 | +105.9% |
| CRNX Crinetics Pharmaceuticals, Inc. | 41.4M | 2.4% | 1.1M | 84.69 | +191.1% |
| BOXX Alpha Architect 1-3 Month Box ETF | 39.2M | 2.3% | 337.1K | 117.96 | +4.1% |
| DNLI Denali Therapeutics Inc. | 35.9M | 2.1% | 1.9M | 24.92 | +71.7% |
| BEAM Beam Therapeutics Inc. | 34.5M | 2.0% | 1.4M | 29.76 | +85.3% |
| ZLAB Zai Lab Ltd | 26.8M | 1.6% | 1.4M | 26.01 | -22.4% |
| SEPN Septerna, Inc. | 26.2M | 1.5% | 1.1M | 40.00 | +260.7% |
| VIR Vir Biotechnology, Inc. | 24.6M | 1.4% | 2.7M | 9.78 | +124.3% |
| DBVT DBV Technologies S.A. | 21.2M | 1.2% | 1.0M | 14.55 | +48.5% |
| AVR Anteris Technologies Global Corp. | 21.0M | 1.2% | 3.8M | 8.98 | +152.2% |
| INSP Inspire Medical Systems, Inc. | 20.9M | 1.2% | 405.2K | 62.36 | -33.0% |
| SRRK Scholar Rock Holding Corp | 20.0M | 1.2% | 407.3K | 56.50 | +64.2% |
| RYTM RHYTHM PHARMACEUTICALS, INC. | 18.4M | 1.1% | 211.4K | 110.00 | +11.4% |
| SYRE Spyre Therapeutics, Inc. | 17.1M | 1.0% | 338.3K | 106.49 | +551.3% |
| CTMX CytomX Therapeutics, Inc. | 16.0M | 0.9% | 3.4M | 3.28 | +66.5% |
| PRTA PROTHENA CORP PUBLIC LTD CO | 15.4M | 0.9% | 1.6M | 9.45 | +10.9% |
| SNY Sanofi | 15.3M | 0.9% | 316.9K | 45.85 | -9.3% |
| PCVX Vaxcyte, Inc. | 15.1M | 0.9% | 259.1K | 62.62 | +100.3% |
| MNPR Monopar Therapeutics | 14.5M | 0.9% | 264.3K | 107.72 | +226.4% |
| ABUS Arbutus Biopharma Corp | 14.1M | 0.8% | 3.1M | 5.21 | +49.3% |
| AMLX Amylyx Pharmaceuticals, Inc. | 13.9M | 0.8% | 1.0M | 38.66 | +381.4% |
| CLDX Celldex Therapeutics, Inc. | 13.6M | 0.8% | 427.8K | 40.38 | +93.3% |
| TSHA Taysha Gene Therapies, Inc. | 13.3M | 0.8% | 3.0M | 6.09 | +112.2% |
| XENE Xenon Pharmaceuticals Inc. | 13.3M | 0.8% | 228.9K | 60.77 | +61.5% |
| STRO SUTRO BIOPHARMA, INC. | 13.1M | 0.8% | 524.4K | 21.04 | +143.4% |
| RVMD Revolution Medicines, Inc. | 13.0M | 0.8% | 133.9K | 209.46 | +479.3% |
| ELVN Enliven Therapeutics, Inc. | 12.9M | 0.8% | 329.5K | 59.82 | +204.3% |
| CGON CG Oncology, Inc. | 12.6M | 0.7% | 185.7K | 79.81 | +212.6% |
| BIL State Street SPDR Bloomberg 1-3 Month T-Bill E | 12.4M | 0.7% | 135.6K | 91.60 | -0.1% |
| ESTA ESTABLISHMENT LABS HOLDINGS INC. | 12.1M | 0.7% | 213.5K | 72.67 | +85.9% |
| REPL Replimune Group, Inc. | 12.1M | 0.7% | 1.6M | 14.77 | +181.3% |
| IVA Inventiva S.A. | 12.1M | 0.7% | 2.2M | 4.68 | +2.2% |
| IONS IONIS PHARMACEUTICALS INC | 12.0M | 0.7% | 160.3K | 59.74 | +39.5% |
| NKTR NEKTAR THERAPEUTICS | 11.6M | 0.7% | 161.3K | 74.02 | +174.7% |
| IKT Inhibikase Therapeutics, Inc. | 11.1M | 0.7% | 6.6M | 2.39 | +42.3% |
| SPRY ARS Pharmaceuticals, Inc. | 10.9M | 0.6% | 1.4M | 5.50 | -62.3% |
| HLXC Helix Acquisition Corp. III | 10.3M | 0.6% | 1.0M | 10.93 | — |
| OVID Ovid Therapeutics Inc. | 10.1M | 0.6% | 4.5M | 2.80 | +194.7% |
| OKUR OnKure Therapeutics, Inc. | 10.1M | 0.6% | 2.4M | 3.94 | +44.3% |
| REGN REGENERON PHARMACEUTICALS, INC. | 9.4M | 0.6% | 12.2K | 834.04 | +41.1% |
| MLTX MoonLake Immunotherapeutics | 8.5M | 0.5% | 457.1K | 15.76 | -70.9% |
| LXEO Lexeo Therapeutics, Inc. | 8.4M | 0.5% | 1.5M | 4.88 | +1.7% |
| IRD Opus Genetics, Inc. | 8.4M | 0.5% | 1.8M | 4.05 | +249.1% |
| TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | 8.1M | 0.5% | 268.4K | 37.34 | +112.0% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →